Ligand Pharma (LGND) Stock Statistics & Valuation Metrics

Ligand Pharma has a market cap or net worth of $3.48B. The enterprise value is $2.03B.

Ligand Pharma has 19,596,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ligand Pharma’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 3.99%.

The current PE Ratio of Ligand Pharma is 48.0. Ligand Pharma’s PEG ratio is 4.53.

In the last 12 months, Ligand Pharma had revenue of 167.13M and earned -4.03M in profits. Earnings per share was -0.22.

In the last 12 months, operating cash flow was 55.35M and capital expenditures -15.38M, giving a free cash flow of 39.97M billion.

Ligand Pharma pays an annual dividend of $0.456, resulting in a dividend yield of ―

Ligand Pharma upcoming earnings date is Nov 5, 2025, After Close (Confirmed).

Ligand Pharma as a current ratio of 8.93, with Debt / Equity ratio of 0.69%

In the past 12 months, Ligand Pharma has paid 6.55M in taxes.

Ligand Pharma EV to EBITDA ratio is 46.44, with an EV/FCF ratio of 19.90.

Ligand Pharma has $245.02M in cash and marketable securities with $5.74M in debt, giving a net cash position of $239.28M billion.

Gross margin is 88.81%, with operating margin of -13.53%, and net profit margin of -2.41%.

The average price target for Ligand Pharma is $182.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy